GlassScriptPhysician profile
Saranya Dinesan
NPI 1568925469
$2,509.30
in general payments reported to CMS, 2019-2025
34 companies · $1,075 in 2025
The $1,075 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $83.45 · 2024: $1,350 · 2025: $1,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,509.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $267.33 | 2024-2025 | |
| Incyte Corporation | $237.01 | 2024-2025 | Jakafi, Monjuvi |
| Celgene Corporation | $229.61 | 2024-2025 | Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $170.74 | 2023-2025 | Iclusig, Alunbrig, Fruzaqla |
| Astellas Pharma US INC | $161.89 | 2024-2025 | Vyloy, Xospata |
| Janssen Biotech, INC. | $159.41 | 2024-2025 | Talvey, Rybrevant, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $128.09 | 2024-2025 | Calquence, Enhertu |
| Pfizer INC. | $109.47 | 2024-2025 | |
| Genzyme Corporation | $108.40 | 2024 | |
| Merck Sharp & Dohme LLC | $92.46 | 2023-2024 | Keytruda, Lynparza, Prevymis |
| Glaxosmithkline, LLC. | $80.75 | 2024-2025 | Jemperli, Zejula, Ojjaara |
| Gilead Sciences, INC. | $75.77 | 2024 | Trodelvy |
| Aveo Pharmaceuticals, INC. | $66.99 | 2025 | |
| Taiho Oncology, INC. | $65.50 | 2025 | |
| Alexion Pharmaceuticals, INC. | $64.74 | 2024-2025 | Ultomiris |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $63.22 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $60.17 | 2024-2025 | Opdivo |
| Novo Nordisk INC | $45.99 | 2024-2025 | Esperoct |
| Array Biopharma INC | $35.15 | 2024 | Braftovi, Mektovi, Lorbrena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.51 | 2025 | |
| Geron Corporation | $23.01 | 2025 | Rytelo |
| Sanofi-Aventis U.S. LLC | $21.40 | 2025 | |
| Jazz Pharmaceuticals INC. | $21.03 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.37 | 2025 | |
| Emd Serono, INC. | $18.37 | 2023 | Bavencio |
| Kite Pharma, INC. | $18.19 | 2025 | Yescarta |
| Genentech USA, INC. | $18.02 | 2024 | Venclexta |
| Janssen Pharmaceuticals, INC | $18.01 | 2024 | Xarelto |
| Lilly USA, LLC | $17.93 | 2024 | Verzenio, Jaypirca |
| Recordati_rare_diseases_inc. | $17.90 | 2024 | Panhematin |
| Azurity Pharmaceuticals, INC. | $16.08 | 2024 | Vivimusta |
| Genmab U.S., INC. | $15.98 | 2024 | Epkinly |
| Servier Pharmaceuticals LLC | $14.34 | 2024 | |
| Abbvie INC. | $13.47 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saranya Dinesan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.